Last edition
News about "BioMarin Pharmaceutical "
US FDA Accepts BioMarin's sNDA for VOXZOGO in Achondroplasia
The US Food and Drug Administration (FDA) has accepted BioMarin's sNDA for VOXZOGO in achondroplasia, supported by long-term safety and efficacy data, including adult height, body proportionality, and arm span outcomes.
BioMarin Pharmaceutical | 14/07/2026 | By News Bureau
BioMarin Strengthens its Leadership with New Appointments
At BioMarin, he will assume responsibility for the company's R&D organization, including discovery research, preclinical, translational and clinical programs, as well as global regulatory and medical affairs.
BioMarin Pharmaceutical | 22/08/2024 | By Aishwarya | 798
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy